What Jasper Therapeutics, Inc.'s executives and directors are doing with their own shares, from SEC Form 3/4/5 filings — separating what the filings state (awards, withholding, disclosed plans) from what only the pattern of dates shows.
| 3 months | 12 months | |
|---|---|---|
| Open-market buys | 0 | 0 |
| Sells | 0 | 0 |
| Total trades | 0 | 0 |
| 3 months | 12 months | |
|---|---|---|
| Acquired | 0 | 0 |
| Disposed | 0 | 0 |
| Net activity | +0 | +0 |
View rich charts and dive into the patterns of specific insiders — who is accumulating, who is winding down, and which sale explanations the filings actually support.
| Insider | Relation | Date | Transaction | Shares | Price | Value | Shares held |
|---|---|---|---|---|---|---|---|
| Lucas Svetlana | Director | Sep 22 | Open-market buy · P | +20,000 | $2.43 | +$48.6K | 20,000 |
| Shizuru Judith Anne | Director | Sep 22 | Open-market buy · P | +41,000 | $2.43 | +$99.6K | 156,901 |
| Wiggans Thomas G | Director | Sep 22 | Open-market buy · P | +41,000 | $2.43 | +$99.6K | 41,000 |
| Martell Ron | President and CEO | Sep 22 | Open-market buy · P | +41,000 | $2.43 | +$99.6K | 74,118 |
| Mahal Jeetinder Singh | Chief Operating Officer | Dec 12 | Disclosed 10b5-1 sale · S | −900 | $22.11 | −$19.9K | 25,009 |
| Mahal Jeetinder Singh | Chief Operating Officer | Dec 12 | Exercise / conversion · M | +900 | $7.10 | +$6.39K | 25,909 |
| Mahal Jeetinder Singh | Chief Operating Officer | Sep 12 | Disclosed 10b5-1 sale · S | −900 | $21.23 | −$19.1K | 25,009 |
| Mahal Jeetinder Singh | Chief Operating Officer | Sep 12 | Exercise / conversion · M | +900 | $7.10 | +$6.39K | 25,909 |
| Mahal Jeetinder Singh | Chief Operating Officer | Jun 12 | Disclosed 10b5-1 sale · S | −900 | $24.16 | −$21.7K | 25,009 |
| Mahal Jeetinder Singh | Chief Operating Officer | Jun 12 | Exercise / conversion · M | +900 | $7.10 | +$6.39K | 25,909 |
| Tucker Edwin Jonathan | Chief Medical Officer | Jun 07 | Grant / award · A | +400 | $4.17 | +$1.67K | 400 |
| Mahal Jeetinder Singh | Chief Operating Officer | Mar 12 | Disclosed 10b5-1 sale · S | −900 | $26.44 | −$23.8K | 25,009 |
| Mahal Jeetinder Singh | Chief Operating Officer | Mar 12 | Exercise / conversion · M | +900 | $7.10 | +$6.39K | 25,909 |
| Velan Capital Investment Management Lp | 10% owner | Feb 08 | Open-market buy · P | +350,000 | $12.95 | +$4.53M | 1,188,500 |
| Carlyle Group Inc. | Insider | Feb 08 | Open-market buy · P | +190,000 | $12.95 | +$2.46M | 1,066,189 |
| Wiggans Thomas G | Director | Nov 28 | Open-market buy · P | +10,000 | $0.65 | +$6.49K | 50,000 |
| Wiggans Thomas G | Director | Nov 21 | Open-market buy · P | +10,000 | $0.64 | +$6.38K | 40,000 |
| Wiggans Thomas G | Director | Nov 20 | Open-market buy · P | +10,000 | $0.63 | +$6.31K | 30,000 |
| Wiggans Thomas G | Director | Nov 17 | Open-market buy · P | +10,000 | $0.60 | +$5.97K | 20,000 |
| Wiggans Thomas G | Director | Nov 16 | Open-market buy · P | +10,000 | $0.60 | +$5.97K | 10,000 |
Loading...
